Banco Santander S.A. Sells 56,839 Shares of Novartis AG (NYSE:NVS)

Banco Santander S.A. cut its position in shares of Novartis AG (NYSE:NVSGet Rating) by 29.0% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 139,100 shares of the company’s stock after selling 56,839 shares during the quarter. Banco Santander S.A.’s holdings in Novartis were worth $12,206,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of NVS. Dimensional Fund Advisors LP grew its position in Novartis by 35.0% during the 4th quarter. Dimensional Fund Advisors LP now owns 3,870,136 shares of the company’s stock worth $338,521,000 after acquiring an additional 1,003,235 shares during the last quarter. Cullen Capital Management LLC grew its position in Novartis by 17.6% during the 1st quarter. Cullen Capital Management LLC now owns 3,295,271 shares of the company’s stock worth $289,160,000 after acquiring an additional 492,643 shares during the last quarter. Fisher Asset Management LLC grew its position in Novartis by 4.7% during the 1st quarter. Fisher Asset Management LLC now owns 10,871,033 shares of the company’s stock worth $953,933,000 after acquiring an additional 486,367 shares during the last quarter. Renaissance Technologies LLC grew its position in Novartis by 12.7% during the 4th quarter. Renaissance Technologies LLC now owns 3,727,570 shares of the company’s stock worth $326,051,000 after acquiring an additional 420,333 shares during the last quarter. Finally, Boston Partners grew its position in Novartis by 6.7% during the 4th quarter. Boston Partners now owns 4,677,403 shares of the company’s stock worth $409,194,000 after acquiring an additional 292,854 shares during the last quarter. 9.40% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

NVS has been the topic of several recent research reports. UBS Group raised their price target on Novartis from CHF 85 to CHF 88 and gave the stock a “neutral” rating in a research report on Wednesday, April 27th. Oppenheimer lowered Novartis from an “outperform” rating to a “market perform” rating in a research report on Friday, June 3rd. JPMorgan Chase & Co. increased their price objective on Novartis from CHF 80 to CHF 81 and gave the stock an “underweight” rating in a report on Wednesday, July 20th. upgraded Novartis from a “hold” rating to a “buy” rating in a report on Thursday, April 14th. Finally, Barclays increased their price objective on Novartis from CHF 80 to CHF 85 in a report on Thursday, April 14th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $87.33.

Novartis Trading Up 0.4 %

NVS opened at $85.57 on Friday. The stock has a market cap of $189.33 billion, a PE ratio of 8.36, a PEG ratio of 2.41 and a beta of 0.51. The company has a quick ratio of 1.13, a current ratio of 1.38 and a debt-to-equity ratio of 0.35. The business has a 50 day moving average of $85.04 and a 200-day moving average of $86.61. Novartis AG has a 52 week low of $79.09 and a 52 week high of $95.17.

Novartis (NYSE:NVSGet Rating) last released its earnings results on Monday, July 18th. The company reported $1.56 EPS for the quarter, beating analysts’ consensus estimates of $1.52 by $0.04. The company had revenue of $12.78 billion during the quarter, compared to analysts’ expectations of $12.78 billion. Novartis had a return on equity of 21.88% and a net margin of 44.31%. The firm’s revenue for the quarter was down 1.4% compared to the same quarter last year. During the same quarter last year, the business posted $1.64 EPS. Equities research analysts predict that Novartis AG will post 6.06 earnings per share for the current fiscal year.

Novartis Company Profile

(Get Rating)

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products.

Featured Stories

Institutional Ownership by Quarter for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.